Memo Therapeutics

OverviewSuggest Edit

Memo Therapeutics is a company operating in the field of antibody discovery and immune repertoire analysis. Its DROPZYLLA platform creates a recombinant in vitro copy of an individual’s B cell and antibody repertoire, which is then banked as a library. The company develops a therapeutic antibody lead pipeline with an initial focus on infectious diseases and cancer.
TypePrivate
Founded2012
HQSchlieren, CH
Websitememo-therapeutics.com

Latest Updates

Employees (est.) (Sept 2021)17
Cybersecurity ratingBMore

Key People/Management at Memo Therapeutics

Karsten Fischer

Karsten Fischer

CEO
Christoph Esslinger

Christoph Esslinger

CSO, Board Member
Simone Schmitt

Simone Schmitt

Director Antibody Development
Robert Schier

Robert Schier

Director
Nadine Geiser

Nadine Geiser

Director
Show more

Memo Therapeutics Office Locations

Memo Therapeutics has an office in Schlieren
Schlieren, CH (HQ)
Wagistrasse 27
Show all (1)

Memo Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2012

Memo Therapeutics total Funding

$22.8 m

Memo Therapeutics latest funding size

$15.42 m

Time since last funding

10 months ago

Memo Therapeutics investors

Memo Therapeutics's latest funding round in November 2020 was reported to be $15.4 m. In total, Memo Therapeutics has raised $22.8 m
Show all financial metrics

Memo Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Memo Therapeutics Online and Social Media Presence

Embed Graph

Memo Therapeutics News and Updates

Swiss biotech Memo Therapeutics lands €13.9 million to advance its COVID-19 antibody treatment

Swiss company Memo Therapeutics AG, an innovator in the field of antibody discovery and immune repertoire analysis, announced today that the company has raised around €13.9 million in Series B financing. The round was led by Swisscanto Invest by Zürcher Kantonalbank and included BERNINA BioInvest, a…

Memo Therapeutics Frequently Asked Questions

  • When was Memo Therapeutics founded?

    Memo Therapeutics was founded in 2012.

  • Who are Memo Therapeutics key executives?

    Memo Therapeutics's key executives are Karsten Fischer, Christoph Esslinger and Simone Schmitt.

  • How many employees does Memo Therapeutics have?

    Memo Therapeutics has 17 employees.

  • Who are Memo Therapeutics competitors?

    Competitors of Memo Therapeutics include Altis Biosystems, Arc Bio and BioMillenia.

  • Where is Memo Therapeutics headquarters?

    Memo Therapeutics headquarters is located at Wagistrasse 27, Schlieren.

  • Where are Memo Therapeutics offices?

    Memo Therapeutics has an office in Schlieren.

  • How many offices does Memo Therapeutics have?

    Memo Therapeutics has 1 office.